There are currently three Food and Drug Administration (FDA)-approved opioid agonist treatments for opioid addiction, which include methadone hydrochloride, buprenorphine hydrochloride, and levo-alpha acetyl methadol (LAAM). All three of these drugs are long-acting opioids, which bind to opioid receptors and thus block opioids from binding to these receptors. LAAM, as well as the other opioid agonist treatments, are long-acting drugs that have minimal psychoactive effects. Use of LAAM thus permits opioid-addicted individuals to engage normally in daily routines while decreasing craving or drug-seeking behaviors.

LAAM may also be labeled as levomethadyl acetate hydrochloride or levacetylmethadol. LAAM was developed in the 1960s and was under investigation as a medication in the treatment of opioid dependence until the 1990s. In 1993, LAAM was approved by the FDA as ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles